Clinical Trial Search

Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 4 — -20.1; -19.9 Units on a scale — p=0.88

Primary: Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity — 8.3 percent

Primary: Change in Menstrual Pain — 4.1 score on a scale — p=<0.0001

Primary: Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Final Visit — 3.01; 2.56 score on a scale

Primary: Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16 — -38.5633 percent…

Primary: Analgesic Requirement — 0.60 (mg/kg)

Primary: Performance Domain of the Patient Satisfaction and Preference Questionnaire (PASAPQ) After 4 Weeks of Treatment — 79.830; 85.112 Scores on a scale — p=0.007

Primary: Number of Participants With Absence of Medication Overuse Headaches (MOH) at Month 6 — 102; 117; 134 Participants — p=0.13

Primary: Numeric Pain Rating Scale (NPRS) — 4; 3 score on a scale

Primary: Pain Level: Numeric Rating Scale — 4.6; 4.5; 4.7; 5.1 score on a scale

Primary: Mean Ocular Surface Staining From Baseline — 0.8; 0.6; 0.5; 0.9 Score on a scale

Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants

Primary: Averaged Pain Score — 3.75; 4.11 score on a scale

Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Score — 17.0; 12.7; 16.4; 25.4 score on a scale — p=0.13

Primary: Percentage of Participants With "Satisfied" or "Very Satisfied" on Item #1 for the CSQ (Cryolipolysis Satisfaction Questionnaire) - Midsection — 83.3 percentage of…